Neurogenetic Studies
CADASIL
The CADASIL study aims to investigate vascular contributions to cognitive impairment and dementia (VCID) by studying Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). This study is designed to investigate how a person’s body, brain, and behavior change throughout the stages of this disease, and what factors might serve as additional risks or protective factors. This study does not provide treatment but seeks to develop the best methods for future clinical care and trials for future potential experimental treatments.
Participation will occur over 5 years and involves neurological exams, cognitive and mood assessments, genetic testing, and completing MRI brain scans and blood draws at three in-person visits over 36 months (about 3 years). Portions of the study visit will be recorded for research purposes, training, and for determining the quality of the data collected.
Contact: Bianca Le
Email: bia7@uw.edu
Ataxia Database
The purpose of this research study is to build a database of hereditary ataxia and hereditary spastic paraplegia patients. The database will include information about each participant’s disease and their contact information. By creating this database, we hope to make it easier for interested subjects to connect with researchers to enroll in studies specifically related to their condition.
The study visit will be completed over the phone, on the computer, or in-person. At this visit study personnel may collect demographic information, medical history, and information related to your mood and cognition. When there is a study that a participant might be interested in, study staff will contact the participant by email or phone.
Contact: Sarah Simon
Email: ssimon3@uw.edu
Viking Therapeutics
The Viking Study is a clinical trial that aims to assess the use of a new investigational drug, VK0214, in individuals diagnosed with an adrenomyeloneuropathy form of the condition X-Linked Adrenoleukodystrophy or X-ALD. Research aims to determine the safety, efficacy, and tolerability of the investigational drug. Participants who meet study requirements will be randomized into 1 of 3 groups; 2 of the groups will receive a dosage of VK0214 and 1 group will receive a Placebo, an inactive drug with no dosage. Participation in the study will last 6 to 8 weeks and may involve overnight stays in the study clinic, administration of the study drug, heart monitoring, blood draws, physical examinations, MRI, and questionnaires.
Contact: Sarah Simon
Email: ssimon3@uw.edu
CRC-SCA
Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA) is an observational study that seeks to further researchers’ understanding of spinocerebellar ataxias (SCAs). Researchers hope to better understand the factors that determine disease progression among Cerebellar Ataxia participants with the goal of improving the understanding of the disease process, current treatments, and development of disease-modifying therapies.
Participation will occur over the course of 5 years and will involve yearly clinic visits that may involve a physical and neurological examinations, questionnaires, collection of your demographic and medical information, blood draws, and an optional Lumbar Puncture.
Contact: Sarah Simon
Email: ssimon3@uw.edu